A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
about
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasisTight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Use of biologic agents in combination with other therapies for the treatment of psoriasisMethotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.Psoriasis: to treat or to manage?Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.Adalimumab: A Review in Chronic Plaque Psoriasis.Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice.Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry.Comprehensive assessment of health education and health promotion in five non-communicable disease demonstration districts in China: a cross-sectional study.Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.Real world prescription trends of methotrexate for psoriasis in Argentina: results of a national survey.Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling.Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).Focus on five patients treated with cyclosporine up to 62 months.S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
P2860
Q26745789-4EE898DC-B4A9-4541-9799-61013ECCF09CQ33651502-181EBE00-F009-4023-A443-D334412C1325Q34553755-4691BAB1-A0BE-498F-9846-FAE7E4D47B6EQ34642567-E82B94A2-A64C-47EB-B668-68675D918E71Q36628064-92763BBC-E186-4E02-AA08-61BB0BF48B76Q37295966-255339C4-4217-48FC-A172-B24F19DDDAFCQ37630778-A1BB7CD1-BC23-468E-9F79-D4741E4B432AQ38153077-8C7C5B8B-F5C0-4138-85E1-4B6435C583EEQ38210780-E6F0309B-E7BE-4006-AB00-7FB00BBFFD66Q38339763-BA96B592-55BE-4F02-AE6E-8A24281860E6Q38639495-75741089-A18C-4408-8FBF-8CEB7BF7776EQ38712213-67293E54-4CBD-413C-B4C1-9F073BCBD289Q38764424-E35FD1EC-32AF-4353-9326-B15C2C6F818DQ38965214-0DAF4AD3-0ED6-46E1-876A-8DB66FD38635Q39046392-812BBFA9-350E-44F8-A968-8FEB05745DA0Q39341410-C90950B7-B898-44A2-9A46-C93A600135ADQ39436442-EEF462CE-26D6-404E-B6D9-5104938D32F8Q40590985-B129A079-73AC-4E23-BA51-F489CD4922FAQ40686340-5B573898-74A6-41D5-B441-0C8151D74264Q41459506-F4E6A774-59F5-4396-BDA7-64178D8AA97CQ41610932-515B0B1E-B8C3-40F8-B3D5-F6B476DF44E3Q47761703-163A4C39-1574-44C1-8CCF-2810D00EEA44Q47873720-874B7013-FB77-44D8-A766-118C127F060EQ47901628-AFD94FA2-4539-4636-B89E-C0ADDA8ABF67Q48104953-A546B314-4806-4C96-B198-9B922AA55F10Q48163817-E1FB3F07-14B6-482C-82E4-5B0CC783882FQ48368354-CD51D95A-4F86-4CE1-A72D-CFE4315A5FB0Q51165648-B3E348CA-565F-4DFD-9576-63E1156A2819Q51201093-6627295F-4071-48B1-8EC0-4D241526C132Q52308590-8D55119F-1D2D-478A-9733-02969AED22CEQ52836583-EA6E3EBD-9110-439E-9826-81E45306760EQ55100632-BBC409EC-4AEE-4256-939E-134C923E8444Q55687055-E29164E0-1EAD-43FC-A8C4-1E91031146C4
P2860
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A consensus report on appropri ...... te-to-severe plaque psoriasis.
@en
type
label
A consensus report on appropri ...... te-to-severe plaque psoriasis.
@en
prefLabel
A consensus report on appropri ...... te-to-severe plaque psoriasis.
@en
P2093
P2860
P356
P1476
A consensus report on appropri ...... ate-to-severe plaque psoriasis
@en
P2093
E M G J de Jong
K Kragballe
U Mrowietz
P2860
P304
P356
10.1111/JDV.12118
P577
2013-02-26T00:00:00Z